title: Cetuximab and panitumumab in a patient with colon cancer and concomitant chronic skin disease: a potential beneficial effect on psoriasis vulgaris.
abstract: Monoclonal antibodies against epidermal growth factor receptor (EGFR) are used in the treatment of advanced colorectal cancer. However, these agents can induce severe dermatological side effects that discourage their administration in patients with chronic dermatological disease. EGFR plays a key role in normal skin development and immunological function, and is expressed in various tissues and organs, although contrarily, it is overexpressed in psoriasis-related skin lesions. Thus, discussion is ongoing regarding the putative pathological role and therapeutic potential of this protein. We herein report on a patient with advanced colon cancer and concomitant long-standing psoriasis vulgaris who received anti-EGFR antibody monotherapy as a third-line treatment for metastatic disease. One week after the initiation of treatment, the patient's skin lesions dramatically subsided and the improvement was sustained during therapy. Based on this case, we propose that anti-EGFR antibody therapy is not necessarily contraindicated in patients with psoriasis vulgaris. Moreover, the findings reaffirmed that EGFR is an important molecule in the pathology of psoriasis.
authors.affiliation: Ken Okamoto, Michiya Kobayashi, Department of Human Health and Medical Sciences, Kochi Medical School Hospital, Kochi 783-8505, Japan.
authors.forename: Ken
authors.initials: K
authors.lastname: Okamoto
authors.affiliation: Ken Okamoto, Michiya Kobayashi, Department of Human Health and Medical Sciences, Kochi Medical School Hospital, Kochi 783-8505, Japan.
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Maeda
authors.affiliation: Ken Okamoto, Michiya Kobayashi, Department of Human Health and Medical Sciences, Kochi Medical School Hospital, Kochi 783-8505, Japan.
authors.forename: Takeo
authors.initials: T
authors.lastname: Shiga
authors.affiliation: Ken Okamoto, Michiya Kobayashi, Department of Human Health and Medical Sciences, Kochi Medical School Hospital, Kochi 783-8505, Japan.
authors.forename: Mai
authors.initials: M
authors.lastname: Shiga
authors.affiliation: Ken Okamoto, Michiya Kobayashi, Department of Human Health and Medical Sciences, Kochi Medical School Hospital, Kochi 783-8505, Japan.
authors.forename: Ken
authors.initials: K
authors.lastname: Dabanaka
authors.affiliation: Ken Okamoto, Michiya Kobayashi, Department of Human Health and Medical Sciences, Kochi Medical School Hospital, Kochi 783-8505, Japan.
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Hanazaki
authors.affiliation: Ken Okamoto, Michiya Kobayashi, Department of Human Health and Medical Sciences, Kochi Medical School Hospital, Kochi 783-8505, Japan.
authors.forename: Michiya
authors.initials: M
authors.lastname: Kobayashi
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068818:Cetuximab / Q000627:therapeutic use*; D002908:Chronic Disease; D003110:Colonic Neoplasms / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000201:enzymology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D000077544:Panitumumab; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011565:Psoriasis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000201:enzymology; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D047428:Protein Kinase Inhibitors; D000077544:Panitumumab; C512478:EGFR protein, human; D066246:ErbB Receptors; D000068818:Cetuximab
keywords: Cetuximab; Colorectal cancer; Epidermal growth factor receptor; Panitumumab; Psoriasis
references.citation: Curr Oncol. 2008 Aug;15(4):196-7
references.pmid: 18769609
references.citation: Br J Dermatol. 2010 Nov;163(5):1085-9
references.pmid: 20716221
references.citation: Australas J Dermatol. 2011 Feb;52(1):56-8
references.pmid: 21332695
references.citation: Acta Oncol. 2004;43(6):592-3
references.pmid: 15370619
references.citation: Arch Toxicol. 2014 Jun;88(6):1189-203
references.pmid: 24770552
references.citation: J Invest Dermatol. 1990 Jun;94(6 Suppl):164S-170S
references.pmid: 2191051
references.citation: Dermatology. 2012;225(2):179-82
references.pmid: 23095682
references.citation: J Invest Dermatol. 1986 Mar;86(3):260-5
references.pmid: 3018088
references.citation: Acta Derm Venereol. 2004;84(4):308-9
references.pmid: 15339078
references.citation: Dis Model Mech. 2012 Jul;5(4):423-33
references.pmid: 22730473
references.citation: Cancer Treat Rev. 2012 Aug;38(5):505-14
references.pmid: 22100458
references.citation: Acta Derm Venereol. 2012 Jul;92(4):360-1
references.pmid: 22565356
references.citation: Nature. 1995 Jul 27;376(6538):337-41
references.pmid: 7630400